Key Points
- Insider buying: CEO Bernd Brust bought 216,212 shares on Nov. 13 at about $3.25 ($702,689) and also bought 157,201 (Nov. 11) and 93,358 (Nov. 12), totaling roughly $1.51 million in recent purchases and boosting his stake to 466,771 shares (an 86.29% increase).
- Company performance: Maravai shares are down ~8.2% after the company missed quarterly estimates (EPS -$0.08 vs. -$0.06; revenue $41.6M vs. $49.0M), with analysts holding a consensus "Hold" rating and an average target of $5.22.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) CEO Bernd Brust acquired 216,212 shares of the business's stock in a transaction on Thursday, November 13th. The shares were purchased at an average price of $3.25 per share, with a total value of $702,689.00. Following the completion of the purchase, the chief executive officer owned 466,771 shares in the company, valued at $1,517,005.75. This represents a 86.29% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Bernd Brust also recently made the following trade(s):
- On Wednesday, November 12th, Bernd Brust bought 93,358 shares of Maravai LifeSciences stock. The stock was purchased at an average price of $3.21 per share, for a total transaction of $299,679.18.
- On Tuesday, November 11th, Bernd Brust purchased 157,201 shares of Maravai LifeSciences stock. The shares were purchased at an average price of $3.24 per share, with a total value of $509,331.24.
Maravai LifeSciences Stock Down 8.2%
NASDAQ MRVI opened at $3.34 on Tuesday. Maravai LifeSciences Holdings, Inc. has a one year low of $1.66 and a one year high of $6.21. The company has a market cap of $854.07 million, a P/E ratio of -3.98 and a beta of 0.34. The business has a fifty day moving average price of $3.07 and a 200 day moving average price of $2.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $41.63 million during the quarter, compared to analysts' expectations of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. Research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. Royal Bank Of Canada decreased their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $5.22.
Get Our Latest Stock Analysis on Maravai LifeSciences
Institutional Investors Weigh In On Maravai LifeSciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its position in Maravai LifeSciences by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company's stock valued at $112,000 after purchasing an additional 5,160 shares during the period. Performa Ltd US LLC raised its holdings in Maravai LifeSciences by 33.3% in the 2nd quarter. Performa Ltd US LLC now owns 22,990 shares of the company's stock valued at $55,000 after buying an additional 5,740 shares during the period. Epacria Capital Partners LLC raised its holdings in Maravai LifeSciences by 6.8% in the 3rd quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company's stock valued at $287,000 after buying an additional 6,384 shares during the period. Ethic Inc. lifted its position in Maravai LifeSciences by 62.8% in the third quarter. Ethic Inc. now owns 16,951 shares of the company's stock valued at $49,000 after buying an additional 6,540 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Maravai LifeSciences by 121.1% during the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company's stock worth $43,000 after buying an additional 9,870 shares during the period. Institutional investors and hedge funds own 50.25% of the company's stock.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
